Recombinant human granulocyte-macrophage colony-stimulating factor as treatment for chronic leg ulcers.
To evaluate the safety and effectiveness of a single subcutaneous perilesional administration of 300 micrograms of recombinant human granulocyte-macrophage colony stimulating factor (rHGM-CSF) for the treatment of chronic leg ulcers. Prospective, descriptive evaluation in an outpatient group. The Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City. 10 patients with chronic leg ulcers. Ulcer diameter and side effects. After 4 weeks observation, 8 of the 10 ulcers had healed; the other two had a mean diameter decrease of 21%. The only side effect was found in a 58 year old female who complained of moderate perilesional pain two days after having received treatment: it was successfully treated with paracetamol. We believe that a single perilesional subcutaneous administration of rhGM-CSF is safe and effective for the treatment of chronic leg ulcers.